Patents Examined by Antonio Galisteo Gonzalez
  • Patent number: 10982291
    Abstract: The specification relates generally to methods of detecting, diagnosing, and/or identifying pathogens, e.g., infectious disease pathogens and determining their drug sensitivity and appropriate methods of treatment. This invention also relates generally to methods of monitoring pathogen infection in individual subjects as well as larger populations of subjects.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: April 20, 2021
    Inventors: James Gomez, Deborah Hung, Amy Barczak
  • Patent number: 10967070
    Abstract: Provided herein are cell penetrating conjugates. The conjugates include a non-cell penetrating protein attached to a phosphorothioate nucleic acid or phosphorothioate polymer backbone, wherein the phosphorothioate nucleic acid or phosphorothioate polymer backbone enhances intracellular delivery of the non-cell penetrating protein. Also provided are compositions and kits comprising the cojugates.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: April 6, 2021
    Assignee: CITY OF HOPE
    Inventors: Andreas Herrmann, Hua Yu, Piotr Marek Swiderski, John Ernest Shively, Lin Li
  • Patent number: 10947291
    Abstract: This document provides methods and materials for treating diabetes. For example, methods and materials for using nucleic acid encoding human preproinsulin to treat diabetes (e.g., type I or type II diabetes) are provided.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: March 16, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Stephen James Russell
  • Patent number: 10947599
    Abstract: The invention provides methods for determining the mutation burden of a tumor by assaying tumor DNA that is representative of genetic loci that are themselves representative of genetics of the tumor. The assayed tumor DNA may be itself agnostic as to loci, so long as it is representative of loci that are representative of tumor mutation burden. The invention provides for assays in which the tumor DNA being sequenced or tested can be something other than, and possibly less than, a full panel of oncogenes that is expected to stand for a tumor's mutational load.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: March 16, 2021
    Inventors: Anthony P. Shuber, William Glover
  • Patent number: 10927383
    Abstract: In certain aspects, the disclosure relates to compositions comprising modified Cas9 polyribonucleotides and methods of use, as well as Cas9 polynucleotides and polyribonucleotides.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: February 23, 2021
    Assignee: ethris GmbH
    Inventors: Manish Kumar Aneja, Rebekka Kubisch-Dohmen, Christian Plank, Carsten Rudolph
  • Patent number: 10907187
    Abstract: Provided are improved fungal strains and use thereof, wherein the fungal strains are capable of producing an altered level of proteins, enzymes, variants and other substances of interest.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: February 2, 2021
    Assignee: DANISCO US INC
    Inventors: Elizabeth A. Bodie, Roman Rabinovich, Aleksandra Virag, Michael Ward, Rochelle Nguyen, James A. Sweigard
  • Patent number: 10908163
    Abstract: The present invention relates to a method for analyzing the interaction between a binding protein and a target material, including measuring the interaction between the binding protein and a target material using an interaction trapper (IT) cell. The IT cell has the binding protein displayed on the surface of intracellular inclusion bodies, i.e., insoluble aggregates, by expressing a fusion protein which forms active protein particles containing the binding protein. The method includes increasing cell permeability without affecting the activity of the binding protein displayed on the cells and genetic information.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: February 2, 2021
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Seung-Goo Lee, Yu Jung Kim, Jongsik Gam, Haseong Kim, Dae-Hee Lee, Heung-Chae Jung
  • Patent number: 10894966
    Abstract: Expression vectors ideal for use in vaccinating individuals against disease based on vaccinia virus and other chordopoxviruses having high expression of recombinant genes and low expression of vector genes in target animals, and low expression of recombinant genes and high expression of vector genes in cells used for propagation.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 19, 2021
    Assignee: The United States of America, as Represented By The Secretary, Department of Health and Human Services
    Inventors: Bernard Moss, Linda S. Wyatt
  • Patent number: 10881730
    Abstract: The disclosure features immunomodulatory therapeutic compositions of an mRNA encoding an activating oncogene mutation peptide and an mRNA encoding a polypeptide that enhances immune responses to the activating oncogene mutation peptide, for example an mRNA encoding an immune potentiator. The disclosure also features methods of using the same, for example, to stimulate anti-cancer immune responses.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 5, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Eric Yi-Chun Huang, Sze-Wah Tse, Jared Iacovelli, Kristine McKinney, Nicholas Valiante
  • Patent number: 10874750
    Abstract: Provided herein are improved gene therapy vectors and methods of use, in some embodiments, comprising sequences for improved expression and cellular targeting of a therapeutic protein.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Hung Do, Steven Tuske, Russell Gotschall, Ce Feng Liu
  • Patent number: 10858660
    Abstract: Control Devices are disclosed including RNA destabilizing elements (RDE), RNA control devices, and destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs) or other transgenes in eukaryotic cells. Multicistronic vectors are also disclosed for use in engineering host eukaryotic cells with the CARs and transgenes under the control of the control devices. These control devices can be used to optimize expression of CARs in the eukaryotic cells so that, for example, effector function is optimized. CARs and transgene payloads can also be engineered into eukaryotic cells so that the transgene payload is expressed and delivered after stimulation of the CAR on the eukaryotic cell.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: December 8, 2020
    Assignee: Chimera Bioengineering, Inc.
    Inventors: Benjamin Wang, Gusti Zeiner
  • Patent number: 10851354
    Abstract: The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member 1 (TRPV1) by expressing PP1? in neurons. The invention also provides HSV vectors for expressing PP1? within neurons and compositions comprising such vectors.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: December 1, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: William F. Goins, Joseph C. Glorioso, III, Justus Bernard Cohen, Bonnie L. Reinhart
  • Patent number: 10829787
    Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 10, 2020
    Inventors: Xin Yu, Xiquan Liang, Xavier de Mollerat du Jeu, Robert Jason Potter
  • Patent number: 10815291
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 27, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Joseph Beene Bolen, Joshua P. Frederick
  • Patent number: 10799602
    Abstract: The invention relates to an RNA comprising at least one open reading frame (ORF) and comprising at least one modification, which increases the expression of the encoded peptide or protein. Furthermore, the invention relates to the medical use of such a modified RNA administered to a subject by jet injection. The invention relates further to a pharmaceutical composition and to a kit of parts comprising said modified RNA for administration by jet injection, preferably for use in the field of gene therapy and/or genetic vaccination. Additionally, the invention relates to a method for enhancing the (localized) expression of RNA-encoded peptides or proteins in the dermis or muscle (of a mammal) comprising administering the modified RNA by jet injection. And finally, the invention relates to a method of treatment comprising administering the modified RNA by jet injection to a subject in need thereof.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 13, 2020
    Assignee: CureVac AG
    Inventor: Patrick Baumhof
  • Patent number: 10801068
    Abstract: The present invention provides a method for treating a human subject afflicted with a metabolic disease with a pharmaceutical composition, comprising the steps of: (i) determining JAG1 expression level in the subject; (ii) identifying the subject as a predicted responder if JAG1 expression level is greater than 1.5 fg/ng 18S; and (iii) administering the pharmaceutical composition to the subject only if the subject is identified as a predicted responder.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: October 13, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Utpal Pajvani
  • Patent number: 10801021
    Abstract: Compositions and methods are provided for measuring population size for a plurality of clonal cell populations in the same individual, e.g., for measuring tumor size for a plurality of clonally independent tumors within the same individual. A subject method can include: (a) contacting an individual with a plurality of cell markers that are heritable and distinguishable from one another, to generate a plurality of distinguishable lineages of heritably marked cells; (b) after sufficient time has passed for the heritably marked cells to undergo at least one round of division, detecting and measuring quantities of at least two of the plurality of cell markers present in the contacted tissue, thereby generating a set of measured values; and (c) using the set of measured values to calculate the number of heritably marked cells that are present (e.g., for at least two of the distinguishable lineages of heritably marked cells).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 13, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Monte M. Winslow, Dmitri Petrov, Ian P. Winters, Christopher McFarland, Zoe N. Rogers
  • Patent number: 10801038
    Abstract: Provided herein are opto-genetic systems, cells, and methods thereof for modulating and regulating genetic expression in transiently active cells. The technologies described herein provide a transformative genetic regulatory tool for in vivo applications, which broadly spans a variety of disciplines, including behavioral, cognitive, and systems neuroscience.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 13, 2020
    Inventor: Adam Tyler Vogel
  • Patent number: 10793854
    Abstract: Provided are a gene involved in the regulation of the amount of melanin in keratinocytes, and the control of the color of skin or hair, the gene being selected from the group consisting of ATG7 gene, RAB11A gene, CLIP-170 gene, Rubicon gene and RAB7B gene, and a molecule encoded by the gene.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 6, 2020
    Assignee: Kao Corporation
    Inventors: Daiki Murase, Akira Hachiya
  • Patent number: 10774354
    Abstract: The present disclosure describes methods and systems for improving the expression of a properly folded, biologically active protein of interest in a cell free synthesis system. The methods and systems use a bacterial cell free extract having an active oxidative phosphorylation system, and include an exogenous protein chaperone. The exogenous protein chaperone can be expressed by the bacteria used to prepare the cell free extract. The exogenous protein chaperone can be a protein disulfide isomerase and/or a peptidyl-prolyl cis-trans isomerase. The inventors discovered that the combination of a protein disulfide isomerase and a peptidyl-prolyl cis-trans isomerase produces a synergistic increase in the amount of properly folded, biologically active protein of interest.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: September 15, 2020
    Inventors: Alice Yam, Dan Groff, Patrick Rivers, Christopher D. Thanos